Isomorphic Labs raises $5 billion in second mega-round in six months
Alphabet's AI drug discovery company has secured $5 billion, led by Greenoaks and Sequoia Capital, to push its pipeline toward clinical trials despite having no approved drugs yet.

Key takeaways
- Isomorphic Labs raised $5 billion, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz as a new backer.
- The round follows a $2.1 billion raise in May 2026, making it the second mega-round in six months.
- Funds will support the IsoDDE drug design platform and move the pipeline toward clinical trials.
- The company works with Novartis, Eli Lilly and Johnson & Johnson but has no approved drug yet.
In this article
A second mega-round in six months
Isomorphic Labs, the AI drug discovery company owned by Alphabet, has raised $5 billion in a new funding round, according to The Decoder. The round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz joining alongside Alphabet and all existing backers.
The deal comes just six months after the company raised $2.1 billion in May 2026. That makes this the second billion-dollar round for Isomorphic Labs within half a year, a pace that underlines investor appetite for AI-driven drug design even before any product reaches the market.
What the money will fund
The company plans to use the fresh capital to advance its in-house platform, IsoDDE, short for Isomorphic Drug Design Engine. According to the company, IsoDDE goes beyond AlphaFold 3 and aims to better predict how drugs bind to targets and where docking sites sit on a molecule.
A second goal is to push the company's drug pipeline closer to clinical trials. Isomorphic Labs already works with Novartis, Eli Lilly and Johnson & Johnson, but it has no approved drug to show for its efforts so far. The new funding is intended to move experimental candidates toward the stage where they can be tested in people.
Leadership and the AlphaFold legacy

Isomorphic Labs was founded in 2021 and is led by Demis Hassabis. In August 2026 he stepped back from running Google DeepMind day to day and took on the role of Alphabet's Chief Scientist. Hassabis shared the 2024 Nobel Prize in Chemistry with John Jumper for their work on AlphaFold, the protein structure prediction system that underpins much of the company's scientific approach.
The original AlphaFold team at DeepMind was disbanded in July 2026. Many of its researchers moved to Isomorphic Labs or were reassigned elsewhere, and nearly a quarter left DeepMind altogether. DeepMind itself continues to publish, shipping AlphaGenome 2 in early November 2026, a model that predicts how DNA variants affect gene activity in specific cell types.
Why the bet matters
The size of the round shows how much confidence investors place in applying AI models to early-stage drug discovery, a field where development timelines are long and failure rates are high. Isomorphic Labs is betting that better prediction of binding and docking can cut the cost and time of finding viable drug candidates.
For readers, the practical test will be whether the pipeline produces candidates that enter clinical trials and, eventually, approved medicines. Until then, the funding is a signal of intent rather than proof of results. The company has not announced a timeline for trial entry, and no approved product exists.
Sources
Spotted a mistake? See our corrections policy. Read how News by OnDevice works in our editorial policy.



